Phosphorous (DrugBank: Phosphorous)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 58 | Hypertrophic cardiomyopathy | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03251287 (ClinicalTrials.gov) | November 2017 | 11/8/2017 | Nitrite in Hypertrophic Cardiomyopathy (HCM) Study | Mechanistic Study of the Effect of Inorganic Sodium Nitrate on Cardiac and Skeletal Muscle Metabolic Efficiency in Patients With Hypertrophic Cardiomyopathy | Cardiomyopathy, Hypertrophic | Drug: Sodium Nitrate;Drug: Placebo;Diagnostic Test: Phosphorous Magnetic Resonance Spectroscopy;Diagnostic Test: Exercise Stress Transthoracic Echocardiogram | University of East Anglia | Norfolk and Norwich University Hospitals NHS Foundation Trust;British Medical Research Council | Recruiting | 18 Years | 80 Years | All | 18 | Phase 1 | United Kingdom |